AAAAAA
Results:
1-13
|
Results: 13
Authors:
Vaziri, SAJ
Krumroy, LM
Elson, P
Budd, GT
Darlington, G
Myles, J
Tubbs, RR
Casey, G
Citation: Saj. Vaziri et al., Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis, CLIN CANC R, 7(7), 2001, pp. 1937-1945
Authors:
Olencki, T
Peereboom, D
Wood, L
Budd, GT
Novick, A
Finke, J
McLain, D
Elson, P
Bukowski, RM
Citation: T. Olencki et al., Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma, J CANC RES, 127(5), 2001, pp. 319-324
Authors:
Link, BK
Budd, GT
Scott, S
Dickman, E
Paul, D
Lawless, G
Fridman, M
Ford, J
Carter, WB
Citation: Bk. Link et al., Delivering adjuvant chemotherapy to women with early-stage breast carcinoma - Current patterns of care, CANCER, 92(6), 2001, pp. 1354-1367
Phase 1 trial of subcutaneous IL-6 in patients with refractory cancer: Clinical and biologic effects
Authors:
Olencki, T
Finke, J
Tubbs, R
Elson, P
McLain, D
Herzog, P
Budd, GT
Gunn, H
Bukowski, RM
Citation: T. Olencki et al., Phase 1 trial of subcutaneous IL-6 in patients with refractory cancer: Clinical and biologic effects, J IMMUNOTH, 23(5), 2000, pp. 549-556
Authors:
van Stolk, R
Stoner, G
Hayton, WL
Chan, K
DeYoung, B
Kresty, L
Kemmenoe, BH
Elson, P
Rybicki, L
Church, J
Provencher, K
McLain, D
Hawk, E
Fryer, B
Kelloff, G
Ganapathi, R
Budd, GT
Citation: R. Van Stolk et al., Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis, CLIN CANC R, 6(1), 2000, pp. 78-89
Authors:
Pelley, R
Ganapathi, R
Wood, L
Rybicki, L
McLain, D
Budd, GT
Peereboom, D
Olencki, T
Bukowski, RM
Citation: R. Pelley et al., A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancer, CANC CHEMOT, 46(3), 2000, pp. 251-254
Authors:
Chidiac, T
Budd, GT
Pelley, R
Sandstrom, K
McLain, D
Elson, P
Crownover, R
Marks, K
Muschler, G
Joyce, M
Zehr, R
Bukowski, R
Citation: T. Chidiac et al., Phase II trial of liposomal doxorubicin (Doxil (R)) in advanced soft tissue sarcomas, INV NEW DR, 18(3), 2000, pp. 253-259
Authors:
Bukowski, RM
Rayman, P
Molto, L
Tannenbaum, CS
Olencki, T
Peereboom, D
Tubbs, R
McLain, D
Budd, GT
Griffin, T
Novick, A
Hamilton, TA
Finke, J
Citation: Rm. Bukowski et al., Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell carcinoma, CLIN CANC R, 5(10), 1999, pp. 2780-2789
Authors:
Gurm, HS
Budd, GT
Citation: Hs. Gurm et Gt. Budd, A 47-year-old man with leiomyosarcoma and altered mental status, CLEV CLIN J, 66(1), 1999, pp. 15-17
Authors:
Adelstein, DJ
Rice, TW
Rybicki, LA
Larto, MA
Koka, A
Taylor, ME
Olencki, TE
Peereboom, DM
Budd, GT
Citation: Dj. Adelstein et al., Mature results from a phase II trial of accelerated induction chemoradiotherapy and surgery for poor prognosis stage III non-small-cell lung cancer, AM J CL ONC, 22(3), 1999, pp. 237-242
Authors:
Budd, GT
Atiba, J
Silver, RT
Palmer, G
Armstrong, S
Otto, K
Presant, C
Citation: Gt. Budd et al., Phase I/II trial of human recombinant granulocyte-colony-stimulating factor (filgrastim) and escalating doses of cyclophosphamide, mitoxantrone, and 5-FU in the treatment of advanced breast cancer, J CANC RES, 125(8-9), 1999, pp. 500-504
Authors:
Budd, GT
Ganapathi, R
Wood, L
Snyder, J
McLain, D
Bukowski, RM
Citation: Gt. Budd et al., Approaches to managing carboplatin-induced thrombocytopenia: Focus on the role of amifostine, SEMIN ONCOL, 26(2), 1999, pp. 41-50
Authors:
Rajagopalan, K
Peereboom, D
Budd, GT
Olencki, T
Murthy, S
Elson, P
McLain, D
Bukowski, R
Citation: K. Rajagopalan et al., Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer, INV NEW DR, 16(3), 1998, pp. 255-258
Risultati:
1-13
|